

Safety, Tolerability and Pharmacokinetic Studies of HRS-2183 for Injection in Healthy Chinese Subjects After Single and Multiple Administration

NCT07232758

Status	RECRUITING
Phase	Phase 1
Sponsor	Jiangsu HengRui Medicine Co., Ltd.
Enrollment	42 participants

Key Eligibility Criteria

Inclusion (4)

- Healthy male and female subjects, aged 18 to 45 years.
- Body weight and Body Mass Index (BMI) within a specified range (e.g., BMI 19.0-26.0 kg/m²).
- Agreement to use highly effective contraception during the study period and for a specified duration after the last dose. No plans for pregnancy, sperm/egg donation.
- Voluntarily provides written informed consent to participate in the study.

Exclusion (17)

- History of significant allergies to any food or drug, especially to the investigational product, its components, or drugs of a similar class.
- History or current presence of any clinically significant disease in major organ systems (e.g., cardiovascular, hepatic, renal, neurological, etc.).
- Any clinically significant abnormalities found during screening assessments (including physical examination, vital signs, and laboratory tests).
- Clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening.
- Evidence of impaired renal function based on laboratory tests (e.g., eGFR, serum creatinine).
- ... and 12 more (see full listing online)

Locations (1 total)

Qilu Hospital of Shandong University, Jinan, Shandong, China